Moreover, cDC1 has a strong ability to cross-presenting antigen, which can effectively induce the activation of initial CD8+ T cells in tumor-draining lymph nodes to enter the tumor foci to synergistically kill tumor cells, and further enhance the anti-tumor effect (Bergamaschi et al., 2020). The gene discussed is CD8A; the disease is neoplasm.